Current state of anti-tumor necrosis factor therapy in autoimmune diseases;Uso de los fármacos antagonistas del factor de necrosis tumoral en las enfermedades autoinmunes: situación actual

Medicina Clinica

Volumn 131, Issue 12, 2008, Pages 471-477

  Sánchez Cano, Daniel ^a   Callejas Rubio, José Luis ^a   Ortego Centeno, Norberto ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Anti TNF; Autoimmune diseases; Inflammatory diseases

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ALLERGIC REACTION; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CANCER RISK; CHORIORETINITIS; CROHN DISEASE; CRYPTOCOCCOSIS; DERMATOMYOSITIS; ENTERITIS; ERYTHEMA NODOSUM; GIANT CELL ARTERITIS; GRAVES DISEASE; HISTOPLASMOSIS; HUMAN; INFECTION; INFECTION RISK; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; NEOPLASM; OFF LABEL DRUG USE; PEMPHIGOID; PEMPHIGUS; POLYARTERITIS NODOSA; POLYMYOSITIS; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERITIS; SCLERODERMA; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UVEITIS; VASCULITIS; WEGENER GRANULOMATOSIS; DRUG ANTAGONISM; IMMUNOLOGY; SKIN DISEASE;

AUTOIMMUNE DISEASES; HUMANS; SKIN DISEASES; TUMOR NECROSIS FACTORS; VASCULITIS;

EID: 63149091693     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13126958     Document Type: Review

References (128)

1. Kourbeti I.S., and Boumpas D.T. Biological therapies of autoimmune diseases. Curr Drug Targets Inflamm Allergy 4 (2005) 41-46
2. Atzeni F., Sarzi-Puttini P., Doria A., Iaccarino L., and Capsoni F. Potential offlabel use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev 4 (2005) 144-152
3. Graves J.E., Nunley K., and Heffernan M.P. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 56 (2007) e55-e79
4. Barrie A., and Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 13 (2007) 1424-1429
5. Langley R.G., Gupta A.K., Cherman A.M., and Inniss K.A. Biologic therapeutics in the treatment of psoriasis. Part 1: review. J Cutan Med Surg 11 (2007) 99-122
6. Baumgart D.C., and Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369 (2007) 1641-1657
7. Hewitt D., and Tait C. Use of infliximab in pyoderma gangrenosum. Australas J Dermatol 48 (2007) 95-98
8. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55 (2006) 505-509
9. Kerns M.J., Graves J.E., Smith D.I., and Heffernan M.P. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg 25 (2006) 226-240
10. Disla E., Quayum B., Cuppari G.G., and Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol 10 (2004) 50-52
11. Fonder M.A., Cummins D.L., Ehst B.D., Anhalt G.J., and Meyerle J.H. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 5 (2006) e8
12. Kugathasan S., Miranda A., Nocton J., Drolet B.A., Raasch C., and Binion D.G. Dermatologic manifestations of Crohn disease in children: response to infliximab. J. Pediatr Gastroenterol Nutr 37 (2003) 150-154
13. Rahier J.F., Lion L., Dewit O., and Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy. Acta Gastroenterol Belg 68 (2005) 376-379
14. Clayton T.H., Walker B.P., and Stables G.I. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 31 (2006) 823-824
15. Ortego-Centeno N., Callejas-Rubio J.L., Sánchez-Cano D., and Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 21 (2007) 408-410
16. Boyd A.S. Etanercept treatment of erythema nodosum. Skinmed 6 (2007) 197-199
17. Jacobi A., Shuler G., and Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 153 (2005) 448-449
18. Pardo J., Mercader P., Mahiques L., Sánchez-Carazo J.L., Oliver V., and Fortea J.M. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 153 (2005) 222-223
19. Berookhim B., Fischer H.D., and Weinberg J.M. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 74 (2004) 245-247
20. Lin M.H., Hsu C.K., and Lee J.Y. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 141 (2005) 680-682
21. Gubinelli E., Bergamo F., Didona B., Annessi G., Atzori F., and Raskovic D. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol 55 (2006) 1107-1108
22. Howell S.M., Bessinger G.T., Altman C.E., and Belnap C.M. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 53 (2005) 541-543
23. Sacher C., Rubbert A., Konig C., Scharffetter-Kochanek K., Krieg T., and Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 46 (2002) 113-115
24. Yamauchi P.S., Lowe N.J., and Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 54 (2006) S121-S122
25. Canizares M.J., Smith D.I., Conners M.S., Maverick K.J., and Heffernan M.P. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 142 (2006) 1457-1461
26. Prey S., Robert P.Y., Drouet M., Sparsa A., Roux C., Bonnetblanc J.M., et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol 87 (2007) 74-75
27. Heffernan M.P., and Bentley D.D. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 142 (2006) 1268-1270
28. Theodossiadis P.G., Markomichelakis N.N., and Sfikakis P.P. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27 (2007) 399-413
29. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52 (2005) 2447-2451
30. Paridaens D., Van den Bosch W.A., Van der Loos T.L., Krenning E.P., and Van Hagen P.M. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 19 (2005) 1286-1289
31. Vázquez-Cobian L.B., Flynn T., and Lehman T.J. Adalimumab therapy for childhood uveitis. J Pediatr 149 (2006) 572-575
32. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D., et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91 (2007) 319-324
33. Guignard S., Gossec L., Salliot C., Ruyssen-Witrand A., Luc M., Duclos M., et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 65 (2006) 1631-1634
34. Rahman M.U., Poe D.S., and Choi H.K. Autoimmune vestibulo-cochlear disorders. Curr Opin Rheumatol 13 (2001) 184-189
35. Matteson E.L., Choi H.K., Poe D.S., Wise C., Lowe V.J., McDonald T.J., et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum 53 (2005) 337-342
36. Cohen S., Shoup A., Weisman M.H., and Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol 26 (2005) 903-907
37. Street I., Jobanputra P., and Proops D.W. Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss. J Laryngol Otol 120 (2006) 1064-1066
38. Van Wijk F., Staecker H., Keithley E., and Lefebvre P.P. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol 11 (2006) 357-365
39. Mukhtyar C., and Luqmani R. Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis. Ann Rheum Dis 64 Suppl 4 (2005) 31-36
40. Svozilkova P., Rihova E., Brichova M., Diblik P., Kuthan P., and Poch T. Infliximab in the treatment of Wegener's granulomatosis: case report. Cesk Slov Oftalmol 62 (2006) 280-286
41. Hermann J., Reittner P., Scarpatetti M., and Graninger W. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis 65 (2006) 691-692
42. El-Shabrawi Y., and Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 19 (2005) 1017-1018
43. Kleinert J., Lorenz M., Kostler W., Horl W., Sunder-Plassmann G., and Soleiman A. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 116 (2004) 334-338
44. Wegener's Granulomatosis Etanercept Trial (WGET) Research, Group, Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
45. Arbach O., Gross W.L., and Gause A. Treatment of refractory Churg-Strausssyndrome (CSS) by TNF-alpha blockade. Immunobiology 206 (2002) 496-501
46. Al-Bishri J., Le Riche N., and Pope J.E. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 32 (2005) 1371-1373
47. Wu K., and Throssell D. A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 21 (2006) 1710-1712
48. Vega Gutiérrez J., Rodríguez Prieto M.A., and García Ruiz J.M. Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 21 (2007) 570-571
49. Feinstein J., and Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 11 (2005) 219-222
50. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behcet's disease - review and basis for recommendations. Rheumatology (Oxford) 46 (2007) 736-741
51. Mushtaq B., Saeed T., Situnayake R.D., and Murray P.I. Adalimumab for sightthreatening uveitis in Behcet's disease. Eye 21 (2007) 824-825
52. Van Laar J.A., Missotten T., Van Daele P.L., Jamnitski A., Baarsma G.S., and Van Hagen P.M. Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis 66 (2007) 565-566
53. Cantini F., Niccoli L., Salvarani C., Padula A., and Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44 (2001) 2933-2935
54. Airo P., Antonioli C.M., Vianelli M., and Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41 (2002) 347-349
55. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., and Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62 (2003) 1116
56. Uthman I., Kanj N., and Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 25 (2006) 109-110
57. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al., Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
58. Tan A.L., Holdsworth J., Pease C., Emery P., and McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62 (2003) 373-374
59. Ahmed M.M., Mubashir E., Hayat S., Fowler M., and Berney S.M. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 26 (2007) 1353-1355
60. Fricker M., Baumann A., Wermelinger F., Villiger P.M., and Helbling A. A novel therapeutic option in Cogan diseases? TNF-alpha blockers. Rheumatol Int 27 (2007) 493-495
61. Denys B.G., Bogaerts Y., Coenegrachts K.L., and De Vriese A.S. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?. Clin Sci (Lond) 112 (2007) 281-289
62. Cruz B.A., Reis D.D., and Araujo C.A. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 27 (2007) 1181-1183
63. Kobylecki C., and Shaunak S. Refractory neurosarcoidosis responsive to infliximab. Pract Neurol 7 (2007) 112-115
64. Uthman I., Touma Z., and Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol 26 (2007) 2001-2003
65. Salama B., Gicquel J.J., Lenoble P., and Dighiero P.L. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 41 (2006) 766-768
66. Saleh S., Ghodsian S., Yakimova V., Henderson J., and Sharma O.P. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 100 (2006) 2053-2059
67. Callejas-Rubio J.L., Ortego-Centeno N., López-Pérez L., and Benticuaga M.N. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25 (2006) 596-597
68. De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 15 (2006) 762-767
69. Lamprecht P. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev 4 (2005) 28-34
70. Hayat S.J., and Uppal S.S. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol 17 (2007) 174-177
71. Micheloud D., Nuño L., Rodríguez-Mahou M., Sánchez-Ramón S., Ortega M.C., Aguaron A., et al. Efficacy and safety of etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 15 (2006) 881-885
72. Ramos-Casals M., Brito-Zeron P., Muñoz S., Soria N., Galiana D., ertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 86 (2007) 242-251
73. Mariette X., Ravaud P., Steinfeld S., Baron G., Goetz J., Hachulla E., et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 50 (2004) 1270-1276
74. Sankar V., Brennan M.T., Kok M.R., Leakan R.A., Smith J.A., Manny J., et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, doubleblind, placebo-controlled pilot clinical trial. Arthritis Rheum 50 (2004) 2240-2245
75. Zandbelt M.M., De Wilde P., Van Damme P., Hoyng C.B., Van de Putte L., and Van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 31 (2004) 96-101
76. Lam G.K., Hummers L.K., Woods A., and Wigley F.M. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34 (2007) 1636-1637
77. Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 36 (2006) 168-172
78. Hengstman G.J., Van den Hoogen F.H., Barrera P., Netea M.G., Pieterse A., Van de Putte L.B., et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50 (2003) 10-15
79. Hengstman G.J., Van den Hoogen F.H., and Van Engelen B.G. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 52 (2004) 61-63
80. Labioche I., Liozon E., Weschler B., Loustaud-Ratti V., Soria P., and Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 43 (2004) 531-532
81. Selva-O'Callaghan A., Martinez-Costa X., Solans-Laque R., Mauri M., Capdevila J.A., and Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 43 (2004) 1196-1197
82. Uthman I., and El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology (Oxford) 43 (2004) 1198-1199
83. Korkmaz C., Temiz G., Cetinbas F., and Buyukkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford) 43 (2004) 937-938
84. Efthimiou P., Schwartzman S., and Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65 (2006) 1233-1236
85. Dold S., Justiniano M.E., Márquez J., and Espinoza L.R. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 26 (2007) 1186-1188
86. Grundtman C., Dastmalchi M., Alexandersson H., Tollbaeck A., Einarsdottir H., Nennesmo I., et al. Potenttially harmful effects of infliximab treatment in patients with idopathic inflammatory myopathies (2004), European League Against Rheumatism, Berlin
87. Saadeh C.K. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy [resumen]. Arthritis Rheum 43 Suppl 9 (2000) 193
88. Sprott H., Glatzel M., and Michel B.A. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 43 (2004) 524-526
89. Iannone F., Scioscia C., Falappone P.C., Covelli M., and Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33 (2006) 1802-1804
90. Musial J., Undas A., and Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42 (2003) 1566-1568
91. Hall H.A., and Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 55 (2006) 982-984
92. Wagner A.D., Andresen J., Jendro M.C., Halsemann J.L., and Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46 (2002) 1965-1968
93. Iqbal M., and Kolodney M.S. Acne fulminans with synovitis-acne-pustulosishyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 52 (2005) S118-S120
94. Massara A., Cavazzini P.L., and Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford) 45 (2006) 730-733
95. Olivieri I., Padula A., Ciancio G., Salvarani C., Niccoli L., and Cantini F. Successful treatment of SAPHO syndrome with infiximab: report of two cases. Ann Rheum Dis 61 (2002) 375-376
96. Fernández-Vozmediano J.M., and Armario-Hita J.C. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 215 (2007) 41-44
97. Usmani N., Clayton T.H., Everett S., and Goodfield M.D. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 32 (2007) 204-205
98. Fardet L., Dupuy A., Kerob D., Levy A., Allez M., Begon E., et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 56 (2007) 624-628
99. Thielen A.M., Barde C., and Saurat J.H. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 155 (2006) 1105-1107
100. Rosi Y.L., Lowe L., and Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 16 (2005) 58-61
101. Adams D.R., Gordon K.B., Devenyi A.G., and Ioffreda M.D. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 139 (2003) 1540-1542
102. Sullivan T.P., Welsh E., Kerdel F.A., Burdick A.E., and Kirsner R.S. Infliximab for hidradenitis suppurativa. Br J Dermatol 149 (2003) 1046-1049
103. Lebwohl B., and Sapadin A.N. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 49 (2003) S275-S276
104. Katsanos K.H., Christodoulou D.K., and Tsianos E.V. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 97 (2002) 2155-2156
105. Martínez F., Nos P., Benlloch S., and Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 7 (2001) 323-326
106. Cusack C., and Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 154 (2006) 726-729
107. Henderson Jr. R.L. Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol 5 (2006) 1010-1011
108. Moul D.K., and Korman N.J. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 42 (2006) 1110-1112
109. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab. J Am Acad Dermatol 55 (2006) 163-164
110. Flores D., Márquez J., Garza M., and Espinoza L.R. Reactive arthritis: newer developments. Rheum Dis Clin North Am 29 (2003) 37-59
111. Oili K.S., Niinisalo H., Korpilähde T., and Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol 32 (2003) 122-124
112. Flagg S.D., Meador R., Hsia E., Kitumnuaypong T., and Schumacher Jr. H.R. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 53 (2005) 613-617
113. Sánchez-Cano D., Callejas-Rubio J.L., and Ortego-Centeno N. Use of adalimumab in poststreptococcal reactive arthritis. J Clin Rheumatol 13 (2007) 176
114. Iizuka M., Konno S., Horie Y., Itou H., Shindo K., and Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 55 (2006) 744-745
115. Boscá M.M., Pérez-Baylach C.M., Solis M.A., Antón R., Mayordomo E., Pons S., et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 55 (2006) 294-295
116. Anelli M.G., Torres D.D., Manno C., Scioscia C., Iannone F., Covelli M., et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 52 (2005) 2519-2520
117. Fernández-Nebro A., Tomero E., Ortiz-Santamaría V., Castro M.C., Olivé A., De Haro M., et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118 (2005) 552-556
118. Stamp L.K., and O'Donnell J.L. HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: response to infliximab. J Rheumatol 32 (2005) 382-385
119. Fiehn C., and Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis 63 (2004) 232
120. Gottenberg J.E., Merle-Vincent F., Bentaberry F., Allanore Y., Berenbaum F., Fautrel B., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48 (2003) 2019-2024
121. Verschueren P., Lensen F., Lerut E., Claes K., De Vos R., Van Damme B., et al. Benefit of anti-TNF alpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 62 (2003) 368-369
122. Kobak S., Oksel F., Kabasakal Y., and Doganavsargil E. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26 (2007) 2191-2194
123. Ravindran J., Shenker N., Bhalla A.K., Lachmann H., and Hawkins P. Case report: response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. Rheumatology (Oxford) 43 (2004) 669-672
124. Hussein M.A., Juturi J.V., Rybicki L., Lutton S., Murphy B.R., and Karam M.A. Etanercept therapy in patients with advanced primary amyloidosis. Med Oncol 20 (2003) 283-290
125. Parra Ruiz J., Ortego Centeno N., and Raya Álvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol 30 (2003) 1657-1658
126. Nash P.T., and Florin T.H. Tumour necrosis factor inhibitors. Med J Aust 183 (2005) 205-208
127. Munteis-Olivas E., Pérez-García C., Roquer-González J., and Maymo-Guarch J. Multiple sclerosis after treatment with anti-TNF-alpha antibodies. Med Clin (Barc) 125 (2005) 759
128. Sánchez-Cano D., Callejas-Rubio J.L., Ortego-Centeno N., and Ruiz-Villaverde R. Urticaria and angioedema in a patient with Behcet's disease treated with adalimumab. Clin Exp Rheumatol 24 5 Suppl 42 (2006) 128